Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

Tumor Biology

Volumn 29, Issue 6, 2008, Pages 371-380

  Molina, Rafael ^a   Auge, Jose Maria ^a   Escudero, Jose Miguel ^a   Marrades, Ramon ^a   Viñolas, Nuria ^a   Carcereny, Emilio ^a   Ramirez, Jose ^a   Filella, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Histological diagnosis; Lung cancer, prognosis; Mucins; Tumor markers; Tumor associated antigens

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; MUCIN; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TAG 72-3 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 57049085895     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000181180     Document Type: Article

References (47)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. CA Cancer J Clin 2000;50:7-33.
2. Schiller JH: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3-13.
3. Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-117.
4. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olad J, Stover D, Strawn JR, Turrisi AT, Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
6. Jorgensen LG, Osterlind K, Genolla J, et al: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74:463-467.
7. Quoix E, Purohit A, Faller-Beau M, Moreau L, Oster JP, Pauli G: Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 2000;30:127-134.
8. Pujol JL, Quantin X, Jacot M, Boher JM, Grenier J, Lamy PJ: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003;39:131-138.
9. Molina R, Filella X, Auge JM: ProGRP: a new biomarker for small cell lung cancer. Clinical Biochem 2004;37:505-511.
10. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake Y, Harada M: Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer 2001;32:61-69.
11. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al: CYFRA 21-1: a new marker in lung cancer. Cancer 1993;72(suppl):707-713.
12. Niklinski J, Burzykowski T, Niklinska W, Laudanski J, Chyczewski L, Rapellino M, Furman M: Preoperative CYFRA 21.1 levels as a prognostic indicator in resected non-small cell lung cancer. Eur Respir J 1998;12:1424-1428.
13. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, et al: CYFRA 21-1 as a biologic marker of non-small cell lung cancer. Chest 1995;108/1:163-169.
14. Molina R, Filella X, Torres MD, et al: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990;36:251-254.
15. Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R, Aznar J: Diagnostic value of SCC, CEA and CYFRA 21-1 in lung cancer: a Bayesian analysis. Eur Resp J 1997;10:603-609.
16. Buccheri G, Ferrigno D, Vola F: Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung cancer 1993;10:21-33.
17. Nisman B, Heching N, Barak V: Serum tumor markers in resectable and non-resectable non-small cell lung cancer. J Tumor Marker Oncol 2000;15:195-207.
18. Molina R, Agusti C, Mañe JM, Filella X, Jo J, Joseph J, Giménez N, EstapéJ, Ballesta AM: CYFRA 21.1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96-101.
19. Molina R, Filella X, AugéJM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J, Viladiu P: Tumour markers (CEA, CA125, CYFRA 21-1, SCC and NSE) in NSCLC patients as aid in histological diagnosis and prognosis: comparison with the main clinical, pathological and anthropomorphic prognostic factors. Tumor Biol 2003;24:209-218.
20. Keller T, Bitterlich N, Hilfenhaus S, Bigl H, Leohardt P: Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profile. J Cancer Res Clin Oncol 1998;124:565-574.
21. Scheulen ME, Klanig H, Wiefelspÿtz JK, Kšmper P, Wagner B, Konietzko N, et al: Pretherapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to CEA, NSE, SCC-Ag, TPA and TPS. Tumor Diagn Ther 1997;18:14-19.
22. Seregni E, Foa P, Bogni A, Botti C, Cataldo I, Sala M, et al: Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC): comparison with TPA, CEA, SCC and NSE. Oncol Reports 1996;3:95-101.
23. Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X, et al: Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 1996;154:725-733.
24. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A: Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995;72:170-173.
25. European Group on Tumor Markers: Consensus recommendations. Anticancer Res 1999;19:2785-2820.
26. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N, Eigenbrodt E: Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 2002;7:145-151.
27. Eberth W, Muley TH: CYFRA 21.1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res 1999;19:2669-2672.
28. Sieber P, Zimmermann A, Reinmiedl J, Muller C, Hoffman H, Dienemann H: CYFRA 21.1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC). Anticancer Res 1999;19:2665-2668.
29. Kao CH, Hsieh JF, Ho YJ, Ding HJ: Cytoqueratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. Lung 1999;177:333-337.
30. Bidart JM, Thuillier F, Augerearu C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-1707.
31. Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T, Barak V: Prognostic value of CYFRA 21.1, TPS, and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999;19:3549-3552.
32. Niklinski J, Furman M, Laudanski J, Kozlowski M: Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1992;1:401-406.
33. Diez M, Torres A, Maestro ML, Gomez A, Pollan M, Lopez JA, Picardo A, Hernando F, Balibrea JL: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA 125 and SCC antigens in resectable non-small cell lung cancer. Br J Cancer 1996;73:1248-1254.
34. Homma-S, Satoh-H, Kagohashi-K, Fujiwara-M, Kamma-H, Sekizawa-K: Production of CA125 by human lung cancer cell lines. Clin Exp Med 2004;4:139-141.
35. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-115.
36. Stahel RA, Ginsberg R, Haveman K, Havemann K, Hirsch FR, Ihde DC, Jassem J: Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119-126.
37. Molina R, Filella X, Torres MD, et al: Evaluation of a new tumor marker, SCC in benign and neoplasic diseases. Clin Chem 1990;36:251-254.
38. Molina R, Filella X, Bruix J, et al: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379-1383.
39. Cases A, Filella X, Molina R, Ballesta AM, López-Revert J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183-186.
40. Duffy MJ: CA19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364-370.
41. Molina R, AgustíC, Filella X, Jo J, Joseph J, Giménez N, Ballesta AM: Study of a new tumor marker, CYFRA 21-1 in malignant and nonmalignant diseases. Tumor Biol 1994;15:318-321.
42. Semjonov A, Albrecht W, Bialk P, et al: Tumour markers in prostatic cancer: EGTM recommendations. Anticancer Res 1999;19:2785-2820.
43. Filella X, Alcover J, Molina R, Rodriguez A, Carretero P, Ballesta AM: Clinical evaluation of fPSA/PSA ratio in the diagnosis of prostate cancer. Eur J Cancer 1997;33:1226-1229.
44. Molina R, Barak V, van Dalen A, et al: Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumor Biol 2005;26:281-293.
45. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J: Tumor antigens CA 19.9, CA 125 and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995;57:205-211.
46. Bonfrer JMG, Duffy MJ, Radtke O, et al: Tumour markers in gynaecological cancers: EGTM recommendations. Anticancer Res 1999;19:2807-2810.
47. Gonzalez AM, Encabo G, Bermejo B, Armengol M: Prognostic value of the glycoprotein TAG-72.3 in patients with gastric cancer. Int J Biol Markers 2001;16:121-125.